NEW YORK, NY--(Marketwire -12/01/11)- Today, www.BrightonMarkets.com announced new reports highlighting Abbott Laboratories (NYSE: ABT - News) and Novartis AG (ADR) (NYSE: NVS - News). Gain market insight with full analysis and research downloads available at www.BrightonMarkets.com/index.php?coa=ABT&cob=NVS.
Upcoming macro-economic 'tides of influence' are buoyed by crisis both home and abroad. Spanish and Italian yields continue to climb as efforts by the European Central Bank have stopped short of establishing sovereign bond guarantees for any one country. The result is historic yields and a grave concern for the solvency of interbank lending. Markets were drawn to concerns over domestic policy stalemates producing downgrade risks. Despite the situation, there continues to be unique value and opportunity found within careful discretion.
Brighton Markets is releasing new coverage on Abbott Laboratories for its current position within the healthcare industry. Abbott Laboratories is engaged in discovery, development, manufacture, and sale of a diversified line of healthcare products. The full research report on Abbott Laboratories (NYSE: ABT - News) is available here: www.BrightonMarkets.com/index.php?coa=ABT.
Brighton Markets has released research on Novartis AG (ADR) for its changing role within the healthcare industry. Novartis AG (Novartis) provides healthcare solutions. The Company's portfolio includes medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products. The Company operates in four divisions: pharmaceuticals, vaccines and diagnostics, sandoz, and consumer health. The full research report on Novartis AG (ADR) (NYSE: NVS - News) is available here: www.BrightonMarkets.com/index.php?cob=NVS.
About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.
- Abbott Laboratories
- Novartis AG